In 2023, it was estimated that there would be 220 deaths due to all cancers among those between 15 and 29 years in Canada. This statistic displays the estimated number of deaths due to all cancers in Canada by age group in 2023.

In 2023, it was estimated that the mortality rate for cancer in Manitoba would be 192.4 deaths due to per 100,000 population. This statistic displays the estimated mortality rate of cancer in Canada by province in 2023.

In 2023, it was estimated that there would be 1,300 deaths due to cancer among males in Saskatchewan. This statistic displays the estimated number of cancer deaths in Canada by province and gender in 2023.

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

In 2023, it was estimated that there would be 130 deaths due to cancer among males in Canada between 15 to 29 years. This statistic displays the estimated number of deaths due to all cancer types in Canada by age group and gender in 2023.

During 2023, it was estimated that there would be a total of 1,900 deaths due to kidney cancer in Canada. Cancer is one of the leading causes of premature death in Canada. This statistic shows the estimated total number of deaths due to cancer in Canada. by cancer type, in 2023.

Nova Scotia has the highest cancer incidence rate of any province in Canada, followed by Newfoundland and Labrador, and Ontario. However, Nunavut has the highest cancer mortality rate of the provinces. In Nunavut there are around 310 deaths from cancer per 100,000 population, compared to a rate of 218 deaths per 100,000 in Newfoundland and Labrador.

New cancer cases

As of 2023, there were around 513 new cancer cases in Canada per 100,000 population. The most common types of cancer in Canada include lung and bronchus cancer, breast cancer, and prostate cancer. Breast cancer is the most common type of cancer among women, while prostate cancer is the second most common type among men. Men have slightly higher rates of lung and bronchus cancer and colorectal cancer.

Cancer mortality

Lung and bronchus cancers have the highest mortality rate of any cancer in Canada, followed by colorectal and pancreas cancer. Men in Canada have around a five percent chance of dying as a result of lung and bronchus cancer. The lifetime probability of dying from any cancer type for males in Canada is around 24 percent.

In 2023, it was estimated that there would be 2,450 cancer deaths in Saskatchewan. Cancer is one of the leading causes of premature death in Canada. This statistic displays the estimated number of deaths due to cancer in Canada by province in 2023.

Canada’s In-vitro Diagnostics Market size was valued at USD 3.15 Billion in 2024 and is projected to reach USD 6.23 Billion by 2032, growing at a CAGR of 9% from 2026 to 2032.

Key Market Drivers

Rising Chronic Disease Prevalence and Diagnostic Needs: The rising burden of chronic illnesses, such as diabetes, cardiovascular diseases, and cancer, is driving the demand for in-vitro diagnostics to ensure timely and accurate disease detection and management. According to the Public Health Agency of Canada, chronic disease prevalence has significantly increased between 2020 and 2023. The Canadian Cancer Society reported 233,900 new cancer cases in 2022, highlighting the critical need for advanced diagnostic technologies. Statistics Canada revealed that approximately 44% of Canadians aged 20 and older live with at least one chronic condition, driving substantial demand for in-vitro diagnostic solutions.

During 2023, it was estimated that there would be 1,250 deaths due to kidney cancer among males in Canada. Cancer is one of the leading causes of premature death in Canada. This statistic shows the estimated number of deaths due to cancer in Canada by cancer type and gender in 2023.

The incidence rate of all cancers in Manitoba was estimated to be 532 cases per 100,000 population among males in 2023. This statistic displays the estimated incidence rate of cancers among males in Canada by province, as of 2023.

For 2023, it was estimated that there would be 5,700 new breast cancer cases among those between 50 and 59 years old in Canada. This statistic displays the estimated number of new breast cancer cases in Canada among females by age group in 2023.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

This statistic displays age-standardized rate of all cancer types among males in Canada between 1988 and 2019, with a forecast for 2020 to 2023. In 2019, the incidence rate for all cancer cases reached 548 per 100,000 population among males. Cancer is one of the leading causes of premature death and almost half the individuals in Canada will develop this disease during their lifetime.

The Canadian mammography market, a segment of the broader global market exhibiting a robust 8.06% CAGR, presents significant growth opportunities. While precise market sizing for Canada is unavailable in the provided data, we can infer its value based on the global market and regional trends. Considering North America's significant contribution to the global mammography market and Canada's robust healthcare infrastructure, the Canadian market likely represents a substantial portion of this. Factors such as an aging population increasing the incidence of breast cancer, rising awareness about preventative healthcare, and technological advancements driving the adoption of advanced imaging technologies like digital mammography and tomosynthesis are key drivers. The increasing prevalence of breast cancer, coupled with government initiatives promoting early detection programs, fuels demand for mammography services across various end-users, including hospitals, specialty clinics, and diagnostic centers. However, challenges remain, such as high equipment costs potentially limiting accessibility in certain regions, and the need for skilled radiologists to interpret the images. The market is segmented by product type (digital, analog, tomosynthesis, others) and end-user, with digital systems expected to dominate due to their superior image quality and efficiency. Looking forward, the Canadian mammography market is poised for sustained growth. Continued technological innovation, especially in AI-powered image analysis and improved screening techniques, will enhance diagnostic accuracy and efficiency. Furthermore, expansion of healthcare infrastructure and increased insurance coverage for mammography services will contribute to market expansion. However, potential restraints include the need for ongoing investment in training and infrastructure to support the adoption of new technologies and the potential impact of economic factors on healthcare spending. Competitive landscape analysis suggests key players in the global mammography market will have a strong presence in Canada, driving competition and further innovation. The market's growth trajectory points towards a promising future, particularly as early detection and treatment become increasingly crucial in improving breast cancer outcomes. Recent developments include: January 2023: The Queen Elizabeth Hospital in Charlottetown purchased a new digital mammography machine to reduce the need for invasive biopsies and for early detection of breast cancers by radiologists to see breast cancers with less radiation delivered to the breast., June 2022: Lunit received commercial approval in Canada for Lunit INSIGHT, the company's AI solution suite for radiology. Canadian medical device regulator Health Canada issued class 2 medical licenses for Lunit's AI solution for a chest x-ray, 'Lunit INSIGHT CXR' and 'Lunit INSIGHT MMG,' an AI solution for mammography.. Key drivers for this market are: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging. Potential restraints include: Growing Burden of Breast Cancer, Technological Advancements in the Field of Breast Imaging. Notable trends are: Digital System are Expected to Witness Significant Growth Over the Forecast Period.

The incidence rate of prostate cancer in Manitoba was estimated to be 119 cases per 100,000 population in males in 2023. This statistic displays the estimated incidence rate of the three most common cancers among males in Canada by province, as of 2023.

The Canadian pharmaceutical market, a significant segment of the broader North American market, exhibits robust growth potential. With a global CAGR of 4.70%, the Canadian market likely mirrors this trend, albeit potentially with slight variations due to specific national healthcare policies and demographics. Considering the provided global market size of $33.34 billion in 2025, a reasonable estimate for the Canadian market size in 2025 might be between $2 billion and $3 billion, representing a substantial portion of the North American market. This is based on Canada's relatively strong economy and developed healthcare system. Key growth drivers include an aging population necessitating increased prescription drug usage, the rising prevalence of chronic diseases like diabetes and cardiovascular conditions, and ongoing innovation in drug development leading to new and more effective treatments. Market trends show a growing preference for generic drugs, driven by cost-consciousness among both consumers and the government. Regulatory changes and pricing pressures from healthcare payers, however, present significant restraints on market expansion. The market is highly segmented, with notable players such as Johnson & Johnson, Novartis, and Pfizer holding significant market share, though smaller companies and generic drug manufacturers are also influential. The segments by therapeutic class (e.g., cardiovascular, oncology) and by drug type (branded vs. generic) indicate diverse opportunities and varying growth rates within the Canadian market. The forecast period (2025-2033) suggests continued expansion, driven by factors mentioned above. However, the rate of growth may fluctuate year-on-year, depending on the introduction of new drugs, changes in healthcare spending, and economic conditions. Competitive intensity remains high, particularly amongst multinational pharmaceutical companies vying for market leadership and smaller companies focused on niche areas or specific therapeutic classes. Strategic partnerships, mergers and acquisitions, and the focus on innovative drug delivery systems will likely shape the competitive landscape in the coming years. Understanding these market dynamics is crucial for stakeholders seeking to capitalize on the opportunities within the Canadian pharmaceutical industry. Recent developments include: October 2023: Panacea Biotec launched Paclitaxel protein-bound particles for injectable suspension (albumin-bound), which is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and adenocarcinoma of the pancreas in the Canadian market through its strategic partner, Apotex Inc. of Canada., March 2023: Natco Pharma introduced a generic version of the cancer drug Pomalidomide Capsules in Canada. It is the first generic alternative to Celgene Corporation’s Pomalyst brand in the country, approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of multiple myeloma in adults.. Key drivers for this market are: Rising Geriatric Population, Rising Incidence of Chronic Disease. Potential restraints include: Rising Geriatric Population, Rising Incidence of Chronic Disease. Notable trends are: The Alimentary Tract and Metabolism Segment is Expected to Register Significant Growth Over the Forecast Period.

It was estimated that in 2023 there would be 8.5 new stomach cancer cases per 100,000 population in Canada. This statistic depicts the estimated rate of new cancer cases in Canada by cancer type, as of 2023.

In 2023, it was estimated that there would be 11.7 new stomach cancer cases among males in Canada per 100,000 population. This statistic displays the estimated rate of new cancer cases in Canada by cancer type and gender in 2023.

For 2023, it was estimated that there would be 25 new lung cancer cases among those between aged 15 to 29 years old. Cancer is one of the leading causes of premature death in Canada. This statistic displays the estimated number of new lung cancer cases in Canada by age group in 2023.